Shilpa Medicare Announce USFDA Approval for ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg.
Posted on February 25, 2019
Shilpa Medicare Ltd has received U.S. Food and Drug Administration approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg.
Imatinib Mesylate Tablets is a generic equivalent of reference listed drug (RLD), Gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended in the label approved by FDA
Related Topics and Keywords
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
